Mike, That might be true in some instances. The only time I try...

Mike,

That might be true in some instances. The only time I try to take any notice of the market is if I start to consider buying or selling.

I don't rely on market movements to evaluate the potential worth of my investment in Noxopharm. What other people think is beyond my control. The test I use is simple. If I had late stage prostrate cancer, would I want Veyonda in the mix with radiotherapy?

On the basis of the data, my crystal clear answer is yes. As it stands, I would also tick yes to each of the compounds under development with Nyrada, with respect to each of their indications as well.

In my opinion, the market is the wrong lens to use in an attempt to predict the future.

I watched a friend of ours die from cancer earlier this year in March. Yes, the chemo gave him more time but he really had no quality of life. Even if at this stage, it doesn't offer a full cure for everyone, on the evidence thus far, Veyonda appears to do both. Big difference.

And with further experimentation, this can only get better on both fronts.